{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(6)"],"submitter":["Marini JC"],"pubmed_abstract":["For biosimilar drug development, it is critical to demonstrate similar physiochemical characteristics, efficacy, and safety of the biosimilar product compared to the reference product. Therefore, pharmacokinetic (PK) and immunogenicity (antidrug antibody, ADA) assays that allow for the demonstration of biosimilarity are critical. Under the auspices of the American Association of Pharmaceutical Scientists (AAPS) Ligand-Binding Assay Bioanalytical Focus Group (LBABFG), a Biosimilars Action Program Committee (APC) was formed in 2011. The goals of this Biosimilars APC were to provide a forum for in-depth discussions on issues surrounding the development and validation of PK and immunogenicity assays in support of biosimilar drug development and to make recommendations thereof. The Biosimilars "],"journal":["The AAPS journal"],"pagination":["1149-58"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4389757"],"repository":["biostudies-literature"],"pubmed_title":["Systematic verification of bioanalytical similarity between a biosimilar and a reference biotherapeutic: committee recommendations for the development and validation of a single ligand-binding assay to support pharmacokinetic assessments."],"pmcid":["PMC4389757"],"pubmed_authors":["Chappell J","Anderson M","Koppenburg V","Coffey T","Marini JC","Oldfield P","Bowsher RR","Cai XY","Gouty D","Kasinath A","Rebarchak S"],"additional_accession":[]},"is_claimable":false,"name":"Systematic verification of bioanalytical similarity between a biosimilar and a reference biotherapeutic: committee recommendations for the development and validation of a single ligand-binding assay to support pharmacokinetic assessments.","description":"For biosimilar drug development, it is critical to demonstrate similar physiochemical characteristics, efficacy, and safety of the biosimilar product compared to the reference product. Therefore, pharmacokinetic (PK) and immunogenicity (antidrug antibody, ADA) assays that allow for the demonstration of biosimilarity are critical. Under the auspices of the American Association of Pharmaceutical Scientists (AAPS) Ligand-Binding Assay Bioanalytical Focus Group (LBABFG), a Biosimilars Action Program Committee (APC) was formed in 2011. The goals of this Biosimilars APC were to provide a forum for in-depth discussions on issues surrounding the development and validation of PK and immunogenicity assays in support of biosimilar drug development and to make recommendations thereof. The Biosimilars ","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Nov","modification":"2025-04-04T07:30:26.814Z","creation":"2019-03-27T01:49:35Z"},"accession":"S-EPMC4389757","cross_references":{"pubmed":["25277165"],"doi":["10.1208/s12248-014-9669-5"]}}